SCHEDULE 13D/A: RTW Investments Boosts Stake in Orchestra Biomed to 21.7% Through Recent Open Market Purchases

RTW Investments, LP and its affiliated funds have increased their beneficial ownership in Orchestra Biomed Holdings, Inc. to 21.7% through recent open market purchases.

Summary

• RTW Investments, LP, along with RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., and Roderick Wong, M.D., collectively beneficially own 8,306,063 shares of Orchestra Biomed Holdings, Inc. Common Stock.
• This represents 21.7% of the Issuer's outstanding Common Stock, based on 38,312,512 shares outstanding as of April 28, 2025.
• On April 29, 2025, the RTW Funds acquired 50,000 shares at $2.53 per share in the open market.
• On April 30, 2025, the RTW Funds acquired an additional 49,900 shares at $2.99 per share in the open market.
• The source of funds used for these Common Stock acquisitions was the working capital of the RTW Funds.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to a significant institutional investor increasing its stake, which can be interpreted as a vote of confidence. However, the disclosure of a past SEC settlement for the reporting entity introduces a minor negative aspect, preventing a higher score.

Positives

• Increased beneficial ownership by a significant institutional investor (RTW Investments) may signal confidence in Orchestra Biomed Holdings, Inc.'s long-term prospects.
• The acquisition of additional shares in the open market demonstrates continued investment interest from a major shareholder.

Negatives

• RTW Investments, L.P. was subject to an SEC settlement in May 2023 for violations related to conflicts of interest disclosure and beneficial ownership reporting, resulting in a $1.4 million civil penalty.

Risks

• The reporting person, RTW Investments, L.P., has a history of regulatory violations, specifically an SEC settlement in May 2023 for issues related to conflicts of interest disclosure and beneficial ownership reporting, which resulted in a $1.4 million civil penalty.

Future Outlook

The document is a Schedule 13D amendment, primarily reporting changes in beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic outlook.

Industry Context

This filing reflects an institutional investor's increased stake in a biomedical holding company. Such increases can be seen as a vote of confidence in the company's long-term prospects within the healthcare and biotechnology sectors, which often attract specialized investment funds like RTW Investments.

Legal Proceedings

• RTW Investments, L.P. entered into a settlement order with the SEC on May 30, 2023, for violations of Sections 206(2) and 206(4) of the Investment Advisors Act of 1940 and Rule 206(4)-7 thereunder (conflicts of interest disclosure), and Section 13(d) of the Exchange Act and Rules 13d-1 and 13d-2 thereunder (beneficial ownership reporting). The settlement included a cease-and-desist order, a censure, and a civil penalty of $1.4 million.

Stakeholder Impact

• Shareholders may view the increased stake by RTW Investments as a positive signal, potentially indicating confidence in the company's future performance and value. This could lead to increased investor interest.

Key Dates

Recommendation

Keywords

Orchestra Biomed Holdings, RTW Investments, Schedule 13D, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Share Acquisition, Biomedical, Healthcare Investment